INTRODUCTION
============

The developing vertebrate heart tube contains an outer layer of myocardium and an inner layer of endocardium separated by an extracellular matrix (ECM) referred to as the cardiac jelly. During heart valve formation, a subset of endocardial cells in the atrioventricular (AV) canal (AVC) region is specified to delaminate, differentiate, and migrate into the cardiac jelly in a process called endocardial-mesenchymal transition (EMT) ([@b1-molcell-37-5-406-7]; [@b4-molcell-37-5-406-7]). For AV valve formation, locally swollen cardiac jelly together with mesenchymal cells derived from AVC endocardial cells form the endocardial cushion; however the extensive remodeling process that occurs subsequently is not clearly understood ([@b1-molcell-37-5-406-7]; [@b4-molcell-37-5-406-7]).

Signal molecules produced from both the myocardium and endocardium in the AVC region are necessary for proper endocardial cushion formation and EMT of endocardial cells ([@b20-molcell-37-5-406-7]). In the initial step of endocardial cushion formation, a bone morphogenetic protein (BMP) signal from AVC myocardium inhibits the expression of chamber-specific genes in the AVC region, while the endocardial cushion is enlarged by increased deposition of ECM or cardiac jelly between the myocardium and endocardium layers in the AVC. Upon receiving a myocardially derived BMP signal, a subset of AVC endocardium cells undergo the EMT process by producing multiple signals such as transforming growth factor β, Notch, and Wnt/β-catenin, and then migrate into the cardiac jelly where they transition into mesenchymal cells that form valve precursors during later development ([@b1-molcell-37-5-406-7]; [@b4-molcell-37-5-406-7]; [@b5-molcell-37-5-406-7]; [@b24-molcell-37-5-406-7]). Therefore, deficiencies in BMP or Notch signal-related genes inhibit or disrupt normal endocardial cushion formation and/or failure of AVC endocardium EMT in the mouse, chick, and zebrafish ([@b9-molcell-37-5-406-7]; [@b22-molcell-37-5-406-7]; [@b28-molcell-37-5-406-7]). In addition, FGFs, VEGFs, NFAT, and HDAC are also prerequisites for normal heart valve development ([@b4-molcell-37-5-406-7]; [@b16-molcell-37-5-406-7]).

Glycosaminoglycan hyaluronan exists as a hydrated gel that expands the extracellular space, regulates ligand availability, and interacts with numerous ECM components including versican, a major constituent of cardiac jelly ([@b1-molcell-37-5-406-7]). Disruption of *hyaluronan synthase 2* (*has2*) or *versican* in mice and zebrafish is reported to abrogate AVC endocardial cushion formation and EMT-associated mesenchymal cell migration, suggesting that an appropriate ECM environment is important for both EMT of AVC endocardium development and formation of the endocardial cushion ([@b3-molcell-37-5-406-7]; [@b23-molcell-37-5-406-7]; [@b25-molcell-37-5-406-7]; [@b31-molcell-37-5-406-7]).

Although there is some debate on whether EMT is a prerequisite for the migration of AVC endocardial cells into the cardiac jelly during endocardial cushion formation in zebrafish, the mature AV valve of the 2-chambered zebrafish adult heart and 4-chambered mammalian valves are structurally similar. In addition, cellular and molecular signaling events occurring during heart valve development are largely conserved between zebrafish and mammals ([@b2-molcell-37-5-406-7]; [@b6-molcell-37-5-406-7]).

Cysteine-rich protein 2 (Crip2) is a Crip-type subgroup of the LIM domain protein family and has two conserved cysteine-rich motifs that contain cysteine and histidine residues with zinc-binding properties ([@b12-molcell-37-5-406-7]; [@b29-molcell-37-5-406-7]). Mouse Crip2 is reported to be highly expressed in the heart, brain, testis, kidney, and lung, and is involved in the dynamics of the cortical actin cytoskeleton by binding PTP-BL, a protein tyrosine phosphatase ([@b30-molcell-37-5-406-7]). In zebrafish, Crip2 is reported to be a target of Wnt3a signaling and regulates smooth muscle cell differentiation ([@b13-molcell-37-5-406-7]) and the development of cardiac neural crest cells during early embryogenesis ([@b27-molcell-37-5-406-7]). However, the direct role of Crip2 in the AV valve formation has not yet been elucidated.

Zebrafish is a useful animal model for studying development of the heart and other circulation systems, including blood and lymphatic vessels ([@b14-molcell-37-5-406-7], [@b15-molcell-37-5-406-7]; [@b17-molcell-37-5-406-7]; [@b18-molcell-37-5-406-7];) because the embryos are transparent and a multitude of transgenic lines that express fluorescent proteins in tissue- and cell-specific manners are readily available. In zebra-fish, the heart can be observed under a dissecting microscope soon after formation of the primitive heart tube. The heart starts beating at 24 h post-fertilization (hpf), heart looping begins at 36 hpf, functional valves are formed by 48 hpf, and heart valve development is complete by approximately 55 hpf ([@b26-molcell-37-5-406-7]).

In this study, we found that *crip2* expression in the AVC endocardial cells, but not in the AVC myocardial cells, in late heart development is critical for heart valve development in zebrafish embryos. Heart looping was disrupted by *crip2* knockdown. Furthermore, Crip2-deficient embryos showed markedly increased expression of the *has2* and *versican a* genes, which are responsible for the synthesis of Versican a and Hyaluronan. We provide data that Crip2 expressed in the AVC endothelial cells plays an important role in cardiac valve formation by suppressing genes involved in the synthesis of Versican a and Hyaluronan, which are essential ECM components in the cardiac jelly and endocardial cushion.

MATERIALS AND METHODS
=====================

Maintenance of zebrafish and collection of embryos
--------------------------------------------------

Zebrafish (*Danio rerio*) were raised and maintained at 28.5°C, and embryos were staged as described in a previous study ([@b19-molcell-37-5-406-7]). Embryos were obtained from spontaneous spawnings and the embryos were manually dechorionated at appropriate stages by using watchmaker's forceps and then fixed using 4% paraformaldehyde in phosphate-buffered saline. *Tg (cmlc2:EGFP)* ([@b7-molcell-37-5-406-7]) and *Tg (flk1:EGFP)* ([@b10-molcell-37-5-406-7]) embryos were used for phenotypic analyses and immunostaining.

Whole-mount *in situ* hybridization and immunostaining
------------------------------------------------------

Antisense digoxigenin-labeled RNA probes for *crip2*, *vmhc, cmlc2, cdh5, bmp4, tbx2b, notch1b, versican a*, and *has2* were generated using *in vitro* transcription with T3, T7, or SP6 RNA polymerase, according to the manufacturer's instructions (Roche, Germany). Whole-mount *in situ* hybridization was performed at the desired embryonic stages, as described by [@b11-molcell-37-5-406-7]. For fluorescent immunostaining, a *crip2* riboprobe was synthesized using fluorescein-12-UTP (Roche). After *in situ* hybridization, transgenic embryos were immunostained by anti-GFP antibody (Santa Cruz Biotechnology, Inc., USA). Processed embryos were photographed using a microscope (Axioskop, Zeiss, Germany) outfitted with a Nikon Coolpix 4500 digital camera system and a laser-scanning confocal microscope (LSM 5 PASCAL).

Antisense morpholino oligonucleotide (MO) and sense mRNA injections
-------------------------------------------------------------------

*crip2* antisense morpholino oligonucleotide (*crip2* MO) was designed and ontained from Gene Tools LLC. (USA) to block the splicing of *crip2* exon 2 and intron 2 and had the following sequence: 5′-CATGCCGAGGTGAGTAAAACAGAGA-3′. To generate *crip2* sense mRNA, the full open reading frame of *crip2* (NM_213497) was cloned into the pCS2+ expression vector. The construct was linearized using *Not*I digestion and capped RNA was synthesized using m^7^G (5′) ppp (5′) G (Roche) and SP6 RNA polymerase (Roche). The integrity of the synthetic RNA was examined on a 0.7% agarose gel. The RNA was diluted to 100 ng/μl and phenol red was added to a final concentration of 0.2% immediately before injection. The synthesized *crip2* MO and sense mRNA were injected into one- or two-cell stage embryos by using a gas driven microinjector (World Precision Instruments, USA).

RESULTS AND DISCUSSION
======================

In an *in situ* hybridization-based screen for candidate genes that regulate heart valve development, we found that *crip2* expression was restricted to the AVC region in 48-hpf zebrafish embryos ([Fig. 1](#f1-molcell-37-5-406-7){ref-type="fig"} and data not shown). Detailed analysis of the gene expression profile showed that *crip2* mRNA was detected in zebrafish embryos at the one-cell stage, indicating that *crip2* was maternally expressed ([Fig. 1A](#f1-molcell-37-5-406-7){ref-type="fig"}). At the shield stage, *crip2* was ubiquitously expressed in the entire embryonic cell ([Fig. 1B](#f1-molcell-37-5-406-7){ref-type="fig"}), but its expression became restricted to the mesodermal region along the anterior-posterior axis at the 10 somite-stage (ss) ([Fig. 1C](#f1-molcell-37-5-406-7){ref-type="fig"}). In 18 ss embryos, *crip2* expression became further restricted to the head and trunk mesoderm, including the somites, lateral plate mesoderm, and notochord posterior edge ([Fig. 1D](#f1-molcell-37-5-406-7){ref-type="fig"}). In 24 hpf embryos, *crip2* transcripts were abundant in the head, trunk, and tail ([Fig. 1E](#f1-molcell-37-5-406-7){ref-type="fig"}). Transverse sections of the posterior trunk region further confirmed its expression in the somitic muscle ([Fig. 1F](#f1-molcell-37-5-406-7){ref-type="fig"}) and blood vessels ([Fig. 1G](#f1-molcell-37-5-406-7){ref-type="fig"}). At 42 hpf, *crip2* expression had mostly disappeared from the head and trunk ([Fig. 1H](#f1-molcell-37-5-406-7){ref-type="fig"}), and new expression appeared in the pharyngeal arch blood vessels ([Fig. 1I](#f1-molcell-37-5-406-7){ref-type="fig"}) and fin buds ([Fig. 1J](#f1-molcell-37-5-406-7){ref-type="fig"}). These gene expression profiling data suggest a function of zygotic Crip2 in mesoderm-derived tissue formation during early embryogenesis.

During heart development, *crip2* expression was observed in the linear heart tube in 24 hpf embryos ([Fig. 1K](#f1-molcell-37-5-406-7){ref-type="fig"}) and its strong expression persisted in the ventricle and AV canal regions at 36 hpf, but was barely detected in the atrium ([Fig. 1L](#f1-molcell-37-5-406-7){ref-type="fig"}). In the looping heart tubes of 42 and 48 hpf embryos, *crip2* expression was decreased in the ventricle and remained only at the AVC and outflow tract ([Figs. 1M](#f1-molcell-37-5-406-7){ref-type="fig"} and [1N](#f1-molcell-37-5-406-7){ref-type="fig"}). When heart valve development was completed at 55 hpf, *crip2* expression at the AVC and outflow tract had started to decrease ([Fig. 1O](#f1-molcell-37-5-406-7){ref-type="fig"}).

In *Tg(flk1:EGFP)* transgenic zebrafish embryos*,* green fluorescent protein (GFP) is expressed in all endothelial cells ([@b10-molcell-37-5-406-7]). To verify which cells express *crip2*, 48 hpf *Tg (flk1:EGFP)* embryos were immunostained with GFP antibodies and then whole-mount *in situ* hybridization was performed using a fluorescent *crip2* riboprobe. Endocardial cells in the ventricle, atrium, and AVC region were visualized using the GFP antibody ([Fig. 1P](#f1-molcell-37-5-406-7){ref-type="fig"}), and expression of *crip2* was detected in cells at the AVC and outflow tract ([Fig. 1Q](#f1-molcell-37-5-406-7){ref-type="fig"}). By merging the images in [Figs. 1P](#f1-molcell-37-5-406-7){ref-type="fig"} and [1Q](#f1-molcell-37-5-406-7){ref-type="fig"}, we confirmed that *crip2* is expressed specifically in the endocardium of the AVC and outflow tract and not in the heart chamber myocardium or endocardium during the late stage of heart development ([Figs. 1R](#f1-molcell-37-5-406-7){ref-type="fig"} and [1S](#f1-molcell-37-5-406-7){ref-type="fig"}).

To evaluate the contribution of *crip2* to late heart development, we designed a *crip2* splice morpholino (*crip2* MO) ([Fig. 2A](#f2-molcell-37-5-406-7){ref-type="fig"}). The *crip2* MO effectively blocked splicing between exon 2 and intron 2 and resulted in a decrease of *crip2* mRNA transcript ([Fig. 2B](#f2-molcell-37-5-406-7){ref-type="fig"}, \*\*) and an increase in the aberrant transcript containing intron 2 ([Fig. 2B](#f2-molcell-37-5-406-7){ref-type="fig"}, \*) in 24 hpf embryos. Similarly, the abundance of the *crip2* mRNA transcripts was clearly reduced by the *crip2* MO ([Figs. 2D](#f2-molcell-37-5-406-7){ref-type="fig"} and [2D](#f2-molcell-37-5-406-7){ref-type="fig"}′) in 24 hpf embryos when compared to non-injection control embryos (NICs; [Figs. 2C](#f2-molcell-37-5-406-7){ref-type="fig"} and [2C](#f2-molcell-37-5-406-7){ref-type="fig"}′) examined using whole-mount *in situ* hybridization.

To analyze the effect of *crip2* knockdown on heart tube formation, we used *Tg (cmlc2:EGFP)* transgenic embryos that express GFP in myocardial cells in both ventricular and atrial portions of the heart tube ([@b7-molcell-37-5-406-7]). Depending on the amount of *crip2* MO injected into one-cell stage embryos, three variable phenotypes were induced in 48 hpf embryos: normal ([Fig. 2E](#f2-molcell-37-5-406-7){ref-type="fig"}), type 1 ([Fig. 2F](#f2-molcell-37-5-406-7){ref-type="fig"}), and type 2 phenotypes ([Fig. 2I](#f2-molcell-37-5-406-7){ref-type="fig"}). In normal embryos, S-shaped heart looping ([Fig. 2G](#f2-molcell-37-5-406-7){ref-type="fig"}′) and typical ring structures in the AVC region (arrow) were observed ([Fig. 2G](#f2-molcell-37-5-406-7){ref-type="fig"}). However, typical ring structures were not formed in the type 1 and type 2 embryos because heart tubes failed to undergo looping ([Figs. 2](#f2-molcell-37-5-406-7){ref-type="fig"} H, 2H′, 2J, and 2J′). Because type 2 morphant embryos ([Fig. 2I](#f2-molcell-37-5-406-7){ref-type="fig"}) showed more severe developmental defects than type 1 morphants, type 1 embryos were selected for further analysis of Crip2 function in heart development. The ratios of the dose-dependent phenotypes were calculated and these data are summarized in [Fig. 2K](#f2-molcell-37-5-406-7){ref-type="fig"}. Collectively, our data demonstrating that morphological heart valve defects occur in *crip2* morphant embryos and that *crip2* expression becomes spatiotemporally restricted to the endocardium of the AVC and outflow tract strongly suggest an important role for Crip2 in heart valve development.

To further assess the function of Crip2 in late heart development, including heart valve formation, we analyzed the expression of cardiac marker genes ([Fig. 3](#f3-molcell-37-5-406-7){ref-type="fig"}). During heart tube assembly, *cardiac myosin light chain 2* (*cmlc2*) is expressed in myocardia throughout both ventricular and atrial portions of the heart tube, whereas v*entricular myosin heavy chain* (*vmhc*) is restricted to the myocardia in the ventricular portion ([@b32-molcell-37-5-406-7]). *VE-cadherin* (*cdh5*), on the other hand, is specifically expressed in the endocardium during heart development ([@b21-molcell-37-5-406-7]). In zebrafish embryos, knockdown of *crip2* did not alter the expression of *vmhc* ([Figs. 3A](#f3-molcell-37-5-406-7){ref-type="fig"} and [3B](#f3-molcell-37-5-406-7){ref-type="fig"}) and *cmlc2* ([Figs. 3C](#f3-molcell-37-5-406-7){ref-type="fig"} and [3D](#f3-molcell-37-5-406-7){ref-type="fig"}). The total abundance of *cdh5* mRNA was also not changed by *crip2* MO ([Figs. 3E](#f3-molcell-37-5-406-7){ref-type="fig"} and [3F](#f3-molcell-37-5-406-7){ref-type="fig"}), suggesting that Crip2 is not involved in the development of myocardium and endocardium comprising the outer layers of heart chambers.

Next, we examined the expression of genes required for the development of the heart valve. *bmp4* is known to be highly expressed specifically in the AVC myocardium in zebrafish embryos ([@b21-molcell-37-5-406-7]). In the *crip2* morphant embryos, *bmp4* was expressed in the AVC region ([Fig. 3H](#f3-molcell-37-5-406-7){ref-type="fig"}, arrows), in a manner similar to that of the control embryos ([Fig. 3G](#f3-molcell-37-5-406-7){ref-type="fig"}). In agreement with this, expression of *tbx2b*, a marker of the AVC myocardium ([@b31-molcell-37-5-406-7]), was also not altered ([Figs. 3I](#f3-molcell-37-5-406-7){ref-type="fig"} and [3J](#f3-molcell-37-5-406-7){ref-type="fig"}, arrows). In mice, Notch promotes EMT during heart valve development and inhibition of Notch activity prevents valve formation in mice and zebrafish ([@b28-molcell-37-5-406-7]). *notch1b*, a mouse *notch1* ortholog, was expressed in the AVC endocardium of 48 hpf zebrafish embryos ([@b8-molcell-37-5-406-7]), thus we tested the expression of *notch1b* in *crip2* morphant embryos. We found that the expression level of *notch1b* detected in the AVC region of morphant embryos was comparable to that of control embryos at 48 hpf ([Figs. 3K](#f3-molcell-37-5-406-7){ref-type="fig"} and [3L](#f3-molcell-37-5-406-7){ref-type="fig"}). This observation indicated that Crip2 is not involved in regulating the EMT process in the AVC endocardium. An appropriate ECM environment in the endocardial cushion is reported to be required for normal heart valve formation ([@b3-molcell-37-5-406-7]; [@b25-molcell-37-5-406-7]). In zebrafish, it is well established that *versican a* and *has2* synthesize versican a and hyaluronan, respectively, and that these genes have restricted expression in the AVC region in 48 hpf embryos ([@b8-molcell-37-5-406-7]). To further investigate whether Crip2 regulates synthesis of ECM components, we analyzed the expression of *versican a* and *has2* in *crip2* morphant embryos. The expression of *versican a* in the AVC region was significantly increased in the morphant embryos ([Fig. 4B](#f4-molcell-37-5-406-7){ref-type="fig"}) compared to the control embryos ([Fig. 4A](#f4-molcell-37-5-406-7){ref-type="fig"}). Similar to *versican a*, the expression of *has2* in the AVC region was markedly upregulated by the knockdown of *crip2* ([Figs. 4C](#f4-molcell-37-5-406-7){ref-type="fig"} and [4D](#f4-molcell-37-5-406-7){ref-type="fig"}). These results imply that Crip2 functions as a negative regulator of ECM-related gene expression during AV valve development.

We also tested whether overexpression of *crip2* could down-regulate *versican a* and *has2* expression. In wild-type embryos, overexpression of *crip2* did not decrease the expression of *versican a* and *has 2*, although severe developmental defects, including curled body and cardiac edema, were observed ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). These results suggested that the expression level of Crip2 in wild-type embryos is sufficient to suppress the expression of *versican a* and *has 2*; thus, further suppression of these ECM genes could not be achieved by the overexpression of *crip2*. Alternatively, Crip2 might require a cofactor to suppress *versican a* and *has 2* expression. Therefore, overexpression of *crip2* alone cannot further suppress the expression of *versican a* and *has 2*.

Adenomatous polyposis coli (APC), a well-known tumor suppressor protein, negatively regulates Wnt/β-catenin signaling ([@b8-molcell-37-5-406-7]). Wnt/β-catenin signaling can be activated by APC inactivation in mutant mice. Moreover, heart valve defects in APC null mice are reported to be caused by increased *versican a* and *has2* expression in the AVC region, indicating that *versican a* and *has2* are transcriptional targets of the Wnt/β-catenin pathway ([@b8-molcell-37-5-406-7]). According to our *crip2* knockdown data, expression of *versican a* and *has2* at the AVC was markedly upregulated, suggesting an antagonistic role of Crip2 towards Wnt/β-catenin signaling that activates *versican a* and *has2* expression. Our results, together with that of previous reports, indicate that either deficiency or over-production of Versican and Has2 causes heart valve defects ([@b8-molcell-37-5-406-7]; [@b25-molcell-37-5-406-7]; [@b31-molcell-37-5-406-7]).

Here, we report a novel function of Crip2 in suppressing the expression of *versican a* and *has2* in the AVC region, which is essential for normal heart valve development. Through its spatiotemporal regulation of gene expression, Crip2 likely contributes to the formation of an appropriate ECM environment in the endocardial cushion region during multiple stages of heart valve development.
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![Expression profile of *crip2* in the developing zebrafish heart. (A--O) Embryos were stained using the *crip2* riboprobe at the desired developmental stages. Lateral (A--E, H, and I), dorsal (J, K), and anterior views (L--O). Images of transverse sections of the trunk region at 24 hpf (F, G). (A--J) *crip2* expression during early zebrafish embryogenesis. Maternal expression at the one-cell stage (A) and ubiquitous expression at the shield stage (B). Expression of *crip2* was detected in the entire mesodermal region at 10 ss (C). At 18 ss, *crip2* expression became restricted to the head and trunk mesoderm region, including the somitic muscle, lateral plate mesoderm, and posterior notochord edge (D). At 24 hpf, *crip2* was highly expressed in the whole embryonic body (E). Expression of *crip2* in the somitic muscle (arrowhead) and blood vessels (arrow) in a transverse section of the trunk region at 24 hpf (F). Enlarged view of *crip2* expression in the blood vessels (arrows) in panel (F) (G). At 42 hpf, *crip2* expression largely decreased in the whole embryonic body (H). However, *crip2* expression increased in the pharyngeal arch blood vessels \[arrowhead in (I)\] and fin buds \[arrowheads in (J)\]. (K--O) Expression of *crip2* in the developing zebrafish heart. At 24 hpf, expression of *crip2* was detected in the linear heart tube as indicated by an arrow (K). At 36 hpf, *crip2* was highly expressed in the ventricle and AVC region (arrows), but it was nearly undetectable in the atrium (L). Expression of *crip2* decreased in the ventricle and was restricted to the AVC region (arrows) and outflow tract (arrowhead) at 42 (M) and 48 hpf (N). At 55 hpf (O), *crip2* expression had mostly disappeared in the ventricle and atrium, but remained in the AVC region (arrows) (O). (P--Q) Laser-scanning confocal images showing fluorescent whole-mount *in situ* hybridization at 48 hpf. All embryos are shown in frontal view. All endocardial cells were marked using an anti-GFP antibody (green) in *Tg(flk1:EGFP)* embryos (P). Fluorescent *crip2* riboprobe (red) was detected at the AVC (arrows) and outflow tract (arrowhead) (Q). Merged image of P and Q showed that only AVC endocardial cells (yellow color) are positive for both *crip2* expression and GFP antibody (R). Enlarged image of the boxed region in R (S). V, ventricle; A, atrium.](molcell-37-5-406-7f1){#f1-molcell-37-5-406-7}

![Knockdown of *crip2* induces a looping defect in the zebrafish embryonic heart. (A) A schematic diagram showing the designed *crip2* morpholino oligonucleotide (*crip2* MO) and RT-PCR primers (F, R1, and R2). (B--D′) The *in vivo* activity of *crip2* MO was evaluated using RTPCR (B). Impaired splicing products of *crip2* mRNA (\*) in the *crip2* morphant embryos (*crip2* MO) was amplified by RT-PCR using primer F/R1 (\*) and primer F/R2 (\*\*) sets. Using the same primers, normally spliced mRNAs in the non-injection control (NIC) embryos were amplified by RT-PCR (221 bp, F/R1 set; 146 bp, F/R2 set). As a negative control, *cmlc2* was amplified. (C--D′) Effect of *crip2* MO was confirmed by whole-mount *in situ* hybridization using a *crip2* riboprobe at 24 hpf. NIC (C, C′) and *crip2* morphant embryos (D, D′). Lateral (C, D) and dorsal views (C′, D′). (E-J′) Phenotypic analysis of the *Tg(cmlc2:EGFP*) NIC and *Tg(cmlc2:EGFP*) *crip2* morphant embryos. Type 1 morphant embryos showed cardiac edema (arrowhead) and a curved trunk (F). Bright--field (E, F, and I) and fluorescence microscopy images (G--H′, J, and J′). Lateral views (E--G, H, I, and J) and frontal views (G′, H′, and J′). The formation of a typical ring structure (arrow) in the AVC region (G) and S-shaped looping in the NIC embryos (G′) were hindered in *crip2* morphant embryos (H, H′). Type 2 morphant embryos showed shortened trunks and tails (arrowhead) (I). Similar to type 1 morphants (H, H′), the formation of the AVC ring structure (arrows) (J) and heart-looping process (J′) were also disrupted in type 2 morphant embryos (J, J′). The dose-dependent effect of *crip2* MO on the generation of the morphant phenotype (K).](molcell-37-5-406-7f2){#f2-molcell-37-5-406-7}

![Knockdown of *crip2* does not affect the expression of myocardial and endocardial marker genes during heart development. (A--L) Whole-mount *in situ* hybridization using *vmhc* (A, B), *cmlc2* (C, D), *cdh5* (E, F), *bmp4* (G, H), *tbx2b* (I, J), and *ntoch1b* (K, L) riboprobes in the NIC (A, C, E, G, I, and K) and *crip2* morphant embryos (B, D, F, H, J, and L) at 24 hpf (A, B) and 48 hpf (C--L). Dorsal views (A, B) and frontal views (C--L). Arrows indicate the AVC region.](molcell-37-5-406-7f3){#f3-molcell-37-5-406-7}

![Increased expression of *versican a* and *has2* in *crip2* morphant embryos. (A--D) Whole-mount *in situ* hybridization data showing expression of *versican a* (A, B) and *has2* (C, D) in the AVC region of 48 hpf embryos. Frontal views of the NIC (A, C) and *crip2* morphant embryos (B, D).](molcell-37-5-406-7f4){#f4-molcell-37-5-406-7}
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